Literature DB >> 33046835

The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.

Maiko Okano1,2, Tadashi Nomizu3, Kazunoshin Tachibana3,4, Miki Nagatsuka3, Masami Matsuzaki3, Naoto Katagata3, Toru Ohtake4, Shiro Yokoyama5, Masami Arai6, Seigo Nakamura5.   

Abstract

BRCA1/2 pathogenic variant prevalence in Japanese breast cancer is unclear. Here, we analyzed BRCA1/2 pathogenic variant prevalence with a particular focus on age factors, using the Japanese HBOC consortium database. All registered subjects were Japanese individuals who underwent BRCA1/2 genetic testing from January 1996 to July 2017 according to the Japanese HBOC consortium database. Cases were extracted and analyzed for each evaluation item. Overall BRCA1 and BRCA2 pathogenic variant prevalence was 11.2% and 9.0% in the cohort of 2366 proband patients, respectively. The age at onset of breast cancer for patients with BRCA1/2 pathogenic variants was significantly lower than that for patients without a BRCA1/2 pathogenic variant. In both BRCA1/2 patients, ages at onset were not statistically significantly different between two subtype groups (ER-positive vs. TNBC). We analyzed the BRCA1/2 pathogenic variant prevalence among age groups in patients with no family history of breast or ovarian cancer. In the TNBC group, the rate of genetic variants was more frequent among younger patients. Our results demonstrated that early breast cancer onset is associated with a BRCA1/2 pathogenic variant in the Japanese population. Younger TNBC patients were more likely to have a BRCA1/2 pathogenic variant irrespective of a family history of breast or ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33046835      PMCID: PMC7843417          DOI: 10.1038/s10038-020-00849-y

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  44 in total

1.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC).

Authors:  H F Vasen; J P Mecklin; P M Khan; H T Lynch
Journal:  Dis Colon Rectum       Date:  1991-05       Impact factor: 4.585

2.  A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.

Authors:  Saundra S Buys; John F Sandbach; Amanda Gammon; Gayle Patel; John Kidd; Krystal L Brown; Lavania Sharma; Jennifer Saam; Johnathan Lancaster; Mary B Daly
Journal:  Cancer       Date:  2017-01-13       Impact factor: 6.860

3.  Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal.

Authors:  P Ghadirian; A Robidoux; E Nassif; G Martin; C Potvin; E Patocskai; R Younan; N Larouche; A Venne; S Zhang; R Royer; S A Narod
Journal:  Clin Genet       Date:  2013-06-05       Impact factor: 4.438

4.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

Authors:  Fergus J Couch; Steven N Hart; Priyanka Sharma; Amanda Ewart Toland; Xianshu Wang; Penelope Miron; Janet E Olson; Andrew K Godwin; V Shane Pankratz; Curtis Olswold; Seth Slettedahl; Emily Hallberg; Lucia Guidugli; Jaime I Davila; Matthias W Beckmann; Wolfgang Janni; Brigitte Rack; Arif B Ekici; Dennis J Slamon; Irene Konstantopoulou; Florentia Fostira; Athanassios Vratimos; George Fountzilas; Liisa M Pelttari; William J Tapper; Lorraine Durcan; Simon S Cross; Robert Pilarski; Charles L Shapiro; Jennifer Klemp; Song Yao; Judy Garber; Angela Cox; Hiltrud Brauch; Christine Ambrosone; Heli Nevanlinna; Drakoulis Yannoukakos; Susan L Slager; Celine M Vachon; Diana M Eccles; Peter A Fasching
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

5.  Characterization of BRCA1 and BRCA2 mutations in a large United States sample.

Authors:  Sining Chen; Edwin S Iversen; Tara Friebel; Dianne Finkelstein; Barbara L Weber; Andrea Eisen; Leif E Peterson; Joellen M Schildkraut; Claudine Isaacs; Beth N Peshkin; Camille Corio; Leoni Leondaridis; Gail Tomlinson; Debra Dutson; Rich Kerber; Christopher I Amos; Louise C Strong; Donald A Berry; David M Euhus; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2006-02-20       Impact factor: 44.544

6.  The cancer-family syndrome: a pragmatic basis for syndrome identification.

Authors:  H T Lynch; P M Lynch
Journal:  Dis Colon Rectum       Date:  1979-03       Impact factor: 4.585

7.  Meta-analysis of BRCA1 and BRCA2 penetrance.

Authors:  Sining Chen; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

8.  Variation of breast cancer risk among BRCA1/2 carriers.

Authors:  Colin B Begg; Robert W Haile; Ake Borg; Kathleen E Malone; Patrick Concannon; Duncan C Thomas; Bryan Langholz; Leslie Bernstein; Jørgen H Olsen; Charles F Lynch; Hoda Anton-Culver; Marinela Capanu; Xiaolin Liang; Amanda J Hummer; Cami Sima; Jonine L Bernstein
Journal:  JAMA       Date:  2008-01-09       Impact factor: 56.272

Review 9.  A systematic review of the international prevalence of BRCA mutation in breast cancer.

Authors:  Nigel Armstrong; Steve Ryder; Carol Forbes; Janine Ross; Ruben Gw Quek
Journal:  Clin Epidemiol       Date:  2019-07-11       Impact factor: 4.790

10.  Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia.

Authors:  Wei Xiong Wen; Jamie Allen; Kah Nyin Lai; Shivaani Mariapun; Siti Norhidayu Hasan; Pei Sze Ng; Daphne Shin-Chi Lee; Sheau Yee Lee; Sook-Yee Yoon; Joanna Lim; Shao Yan Lau; Brennan Decker; Karen Pooley; Leila Dorling; Craig Luccarini; Caroline Baynes; Don M Conroy; Patricia Harrington; Jacques Simard; Cheng Har Yip; Nur Aishah Mohd Taib; Weang Kee Ho; Antonis C Antoniou; Alison M Dunning; Douglas F Easton; Soo Hwang Teo
Journal:  J Med Genet       Date:  2017-10-09       Impact factor: 6.318

View more
  5 in total

1.  The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.

Authors:  Jarbas Maciel de Oliveira; Nuria Bengala Zurro; Antonio Victor Campos Coelho; Marcel Pinheiro Caraciolo; Rodrigo Bertollo de Alexandre; Murilo Castro Cervato; Renata Moldenhauer Minillo; George de Vasconcelos Carvalho Neto; Ivana Grivicich; João Bosco Oliveira
Journal:  Eur J Hum Genet       Date:  2022-05-09       Impact factor: 5.351

Review 2.  An Overview on Radiation Sensitivity in Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Diana Gonçalves; Ana Salomé Pires; Inês A Marques; Inês Gomes; Gabriela Sousa; Maria Filomena Botelho; Ana Margarida Abrantes
Journal:  Cancers (Basel)       Date:  2022-07-02       Impact factor: 6.575

Review 3.  Investigating the Anticancer Potential of Salvicine as a Modulator of Topoisomerase II and ROS Signaling Cascade.

Authors:  Dipta Dey; Mohammad Mehedi Hasan; Partha Biswas; Stavros P Papadakos; Rehab A Rayan; Sabiha Tasnim; Muhammad Bilal; Mohammod Johirul Islam; Farzana Alam Arshe; Efat Muhammad Arshad; Maisha Farzana; Tanjim Ishraq Rahaman; Sumit Kumar Baral; Priyanka Paul; Shabana Bibi; Md Ataur Rahman; Bonglee Kim
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

4.  Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy.

Authors:  Masayuki Sekine; Takayuki Enomoto; Masami Arai; Hiroki Den; Hiroyuki Nomura; Takeshi Ikeuchi; Seigo Nakamura
Journal:  J Gynecol Oncol       Date:  2022-03-31       Impact factor: 4.756

5.  Is adjuvant chemotherapy necessary in older patients with breast cancer?

Authors:  Midori Morita; Akihiko Shimomura; Emi Tokuda; Yoshiya Horimoto; Yukino Kawamura; Yumiko Ishizuka; Katsutoshi Sekine; Sayaka Obayashi; Yuki Kojima; Yukari Uemura; Toru Higuchi
Journal:  Breast Cancer       Date:  2022-01-15       Impact factor: 3.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.